GlassScriptPhysician profile
Marvin Rene Moszkowicz
NPI 1184612020
$11,537.03
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,034 · 2020: $2,137 · 2021: $2,252 · 2022: $2,407 · 2023: $2,257 · 2024: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,622 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,622.20 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,818.96 | 2019-2024 | Briviact, Nayzilam |
| Sunovion Pharmaceuticals INC. | $1,629.06 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,427.49 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Astellas Pharma US INC | $940.63 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $749.93 | 2021-2024 | Ingrezza |
| Novo Nordisk INC | $476.12 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Sumitomo Pharma America, INC. | $390.99 | 2023-2024 | Gemtesa, Aptiom |
| Janssen Pharmaceuticals, INC | $363.66 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $302.88 | 2020-2024 | Caplyta |
| Acadia Pharmaceuticals INC | $283.02 | 2019-2023 | Nuplazid |
| Amgen INC. | $271.67 | 2019-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $270.55 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $256.33 | 2019-2023 | Hetlioz, Fanapt |
| Abbvie INC. | $233.21 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $232.08 | 2021-2023 | Nuedexta, Rexulti, Abilify Maintena |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Moszkowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.